113 related articles for article (PubMed ID: 15909814)
21. Alpha-fetoprotein antagonizes X-linked inhibitor of apoptosis protein anticaspase activity and disrupts XIAP-caspase interaction.
Dudich E; Semenkova L; Dudich I; Denesyuk A; Tatulov E; Korpela T
FEBS J; 2006 Aug; 273(16):3837-49. PubMed ID: 16869888
[TBL] [Abstract][Full Text] [Related]
22. alpha-Fetoprotein shields hepatocellular carcinoma cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand.
Li M; Zhou S; Liu X; Li P; McNutt MA; Li G
Cancer Lett; 2007 May; 249(2):227-34. PubMed ID: 17046153
[TBL] [Abstract][Full Text] [Related]
23. Radiation-induced apoptosis along with local and systemic cytokine elaboration is associated with DC plus radiotherapy-mediated renal cell tumor regression.
Huang J; Wang Y; Guo J; Lu H; Lin X; Ma L; Teitz-Tennenbaum S; Chang AE; Li Q
Clin Immunol; 2007 Jun; 123(3):298-310. PubMed ID: 17449328
[TBL] [Abstract][Full Text] [Related]
24. The use of alpha-fetoprotein for the treatment of autoimmune diseases and cancer.
Pak VN
Ther Deliv; 2018 Jan; 9(1):37-46. PubMed ID: 29216804
[TBL] [Abstract][Full Text] [Related]
25. Oxidative stress and lymphocyte persistence: implications in immunotherapy.
Mehrotra S; Mougiakakos D; Johansson CC; Voelkel-Johnson C; Kiessling R
Adv Cancer Res; 2009; 102():197-227. PubMed ID: 19595310
[TBL] [Abstract][Full Text] [Related]
26. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
[TBL] [Abstract][Full Text] [Related]
27. Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy.
Sega EI; Lu Y; Ringor M; Leamon CP; Low PS
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):559-66. PubMed ID: 18411004
[TBL] [Abstract][Full Text] [Related]
28. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
van Houdt IS; Oudejans JJ; van den Eertwegh AJ; Baars A; Vos W; Bladergroen BA; Rimoldi D; Muris JJ; Hooijberg E; Gundy CM; Meijer CJ; Kummer JA
Clin Cancer Res; 2005 Sep; 11(17):6400-7. PubMed ID: 16144945
[TBL] [Abstract][Full Text] [Related]
29. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
30. Carbon nanotubes conjugated to tumor lysate protein enhance the efficacy of an antitumor immunotherapy.
Meng J; Meng J; Duan J; Kong H; Li L; Wang C; Xie S; Chen S; Gu N; Xu H; Yang XD
Small; 2008 Sep; 4(9):1364-70. PubMed ID: 18720440
[TBL] [Abstract][Full Text] [Related]
31. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
32. The influence of a human embryonic stem cell-derived microenvironment on targeting of human solid tumor xenografts.
Tzukerman M; Rosenberg T; Reiter I; Ben-Eliezer S; Denkberg G; Coleman R; Reiter Y; Skorecki K
Cancer Res; 2006 Apr; 66(7):3792-801. PubMed ID: 16585206
[TBL] [Abstract][Full Text] [Related]
33. A case of an alpha-fetoprotein-producing intrahepatic cholangiocarcinoma suggests probable cancer stem cell origin.
Ishikawa K; Sasaki A; Haraguchi N; Yoshikawa Y; Mori M
Oncologist; 2007 Mar; 12(3):320-4. PubMed ID: 17405896
[TBL] [Abstract][Full Text] [Related]
34. Alpha-fetoprotein-positive carcinoma of the pancreas: a case report.
Mueller SB; Micke O; Herbst H; Schaefer U; Willich N
Anticancer Res; 2005; 25(3A):1671-4. PubMed ID: 16033080
[TBL] [Abstract][Full Text] [Related]
35. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
36. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
Dong Xda E; Ito N; Lotze MT; Demarco RA; Popovic P; Shand SH; Watkins S; Winikoff S; Brown CK; Bartlett DL; Zeh HJ
J Immunother; 2007 Sep; 30(6):596-606. PubMed ID: 17667523
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
38. Vitamin E analogues and immune response in cancer treatment.
Tomasetti M; Neuzil J
Vitam Horm; 2007; 76():463-91. PubMed ID: 17628186
[TBL] [Abstract][Full Text] [Related]
39. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
Beck SD; Foster RS; Bihrle R; Donohue JP
Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
[TBL] [Abstract][Full Text] [Related]
40. [Limbic encephalitis: the new cell membrane antigens and a proposal of clinical-immunological classification with therapeutic implications].
Dalmau J; Bataller L
Neurologia; 2007 Oct; 22(8):526-37. PubMed ID: 18000762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
